Nasdaq:US$34.13 (+0.27) | HKEX:HK$55.55 (+0.55) | AIM:£5.14 (+0)
Search Result
Previous Article   |   Next Article
Scientific Publications | 3 Nov 2021

NANETS 2021: Interim Analysis Results of Surufatinib in US Patients with Neuroendocrine Tumors